Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.

[1]  M. Levine,et al.  Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates. , 2013, Vaccine.

[2]  J. Wrammert,et al.  Antibody-Secreting Cell Responses after Vibrio cholerae O1 Infection and Oral Cholera Vaccination in Adults in Bangladesh , 2013, Clinical and Vaccine Immunology.

[3]  R. Grais,et al.  Use of a Cholera Rapid Diagnostic Test during a Mass Vaccination Campaign in Response to an Epidemic in Guinea, 2012 , 2013, PLoS neglected tropical diseases.

[4]  R. Barrangou,et al.  Antibiotic Resistance in Salmonella enterica Serovar Typhimurium Associates with CRISPR Sequence Type , 2013, Antimicrobial Agents and Chemotherapy.

[5]  Ji‐Won Kim,et al.  Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. , 2013, Vaccine.

[6]  M. Suar,et al.  Evaluation of Salmonella enterica Serovar Typhimurium TTSS-2 Deficient fur Mutant as Safe Live-Attenuated Vaccine Candidate for Immunocompromised Mice , 2012, PloS one.

[7]  P. Barrow,et al.  Humoral and cellular immune response generated by different vaccine programs before and after Salmonella Enteritidis challenge in chickens. , 2012, Vaccine.

[8]  Jie Li,et al.  Antibiotic resistance of Vibrio cholerae O1 El Tor strains from the seventh pandemic in China, 1961-2010. , 2012, International journal of antimicrobial agents.

[9]  Balamurugan Periaswamy,et al.  Live Attenuated S. Typhimurium Vaccine with Improved Safety in Immuno-Compromised Mice , 2012, PloS one.

[10]  T. Klaenhammer,et al.  Construction and Immunological Evaluation of Dual Cell Surface Display of HIV-1 Gag and Salmonella enterica Serovar Typhimurium FliC in Lactobacillus acidophilus for Vaccine Delivery , 2012, Clinical and Vaccine Immunology.

[11]  Balamurugan Periaswamy,et al.  A Novel Phage Element of Salmonella enterica Serovar Enteritidis P125109 Contributes to Accelerated Type III Secretion System 2-Dependent Early Inflammation Kinetics in a Mouse Colitis Model , 2012, Infection and Immunity.

[12]  Jie Li,et al.  Multiple Antibiotic Resistance of Vibrio cholerae Serogroup O139 in China from 1993 to 2009 , 2012, PloS one.

[13]  W. Ko,et al.  Non-typhoidal Salmonella bacteraemia in elderly patients: an increased risk for endovascular infections, osteomyelitis and mortality , 2012, Epidemiology and Infection.

[14]  M. Levine,et al.  Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains , 2011, Infection and Immunity.

[15]  Henrik C Wegener,et al.  Global monitoring of Salmonella serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007. , 2011, Foodborne pathogens and disease.

[16]  S. Yaron,et al.  Active Suppression of Early Immune Response in Tobacco by the Human Pathogen Salmonella Typhimurium , 2011, PloS one.

[17]  S. Pukatzki,et al.  Antibiotic resistance mechanisms of Vibrio cholerae. , 2011, Journal of medical microbiology.

[18]  A. Shiau,et al.  T cell augments the antitumor activity of tumor-targeting Salmonella , 2011, Applied Microbiology and Biotechnology.

[19]  J. Sirard,et al.  The Microbiota Mediates Pathogen Clearance from the Gut Lumen after Non-Typhoidal Salmonella Diarrhea , 2010, PLoS pathogens.

[20]  Joaquín Bernal-Bayard,et al.  The Salmonella Type III Secretion Effector, Salmonella Leucine-rich Repeat Protein (SlrP), Targets the Human Chaperone ERdj3* , 2010, The Journal of Biological Chemistry.

[21]  A. Faruque,et al.  Transferable Quinolone Resistance in Vibrio cholerae , 2009, Antimicrobial Agents and Chemotherapy.

[22]  J. Glenn Morris,et al.  Cholera transmission: the host, pathogen and bacteriophage dynamic , 2009, Nature Reviews Microbiology.

[23]  J. Holmgren,et al.  Establishment of an Adult Mouse Model for Direct Evaluation of the Efficacy of Vaccines against Vibrio cholerae , 2009, Infection and Immunity.

[24]  Q. K. Fatt,et al.  Annals of Clinical Microbiology and Antimicrobials Non-typhoidal Salmonella Bacteraemia: Epidemiology, Clinical Characteristics and Its' Association with Severe Immunosuppression , 2022 .

[25]  M. Hensel,et al.  Construction of highly attenuated Salmonella enterica serovar Typhimurium live vectors for delivering heterologous antigens by chromosomal integration. , 2008, Microbiological research.

[26]  R. Curtiss,et al.  Immunogenicity of Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Strains Carrying a Gene That Encodes Eimeria tenella Antigen SO7 , 2008, Infection and Immunity.

[27]  Olivier Restif,et al.  Modelling within-Host Spatiotemporal Dynamics of Invasive Bacterial Disease , 2008, PLoS biology.

[28]  Samuel I. Miller,et al.  Salmonellae interplay with host cells , 2008, Nature Reviews Microbiology.

[29]  S. Clare,et al.  Candidate Live, Attenuated Salmonella enterica Serotype Typhimurium Vaccines with Reduced Fecal Shedding Are Immunogenic and Effective Oral Vaccines , 2007, Infection and Immunity.

[30]  E. Hohmann,et al.  Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. , 2006, Vaccine.

[31]  M. Waldor,et al.  SXT-Related Integrating Conjugative Element in New World Vibrio cholerae , 2006, Applied and Environmental Microbiology.

[32]  D. Sack,et al.  An improved technique for isolation of environmental Vibrio cholerae with epidemic potential: monitoring the emergence of a multiple-antibiotic-resistant epidemic strain in Bangladesh. , 2006, The Journal of infectious diseases.

[33]  B. Stecher,et al.  Role of the Salmonella Pathogenicity Island 1 Effector Proteins SipA, SopB, SopE, and SopE2 in Salmonella enterica Subspecies 1 Serovar Typhimurium Colitis in Streptomycin-Pretreated Mice , 2004, Infection and Immunity.

[34]  J. Morris,et al.  Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  M. Hogardt,et al.  Pretreatment of Mice with Streptomycin Provides a Salmonella enterica Serovar Typhimurium Colitis Model That Allows Analysis of Both Pathogen and Host , 2003, Infection and Immunity.

[36]  Y. Kikuchi,et al.  Oral Immunization with ATP-Dependent Protease-Deficient Mutants Protects Mice against Subsequent Oral Challenge with Virulent Salmonella enterica Serovar Typhimurium , 2003, Infection and Immunity.

[37]  Marcia M. Miller,et al.  Association of MHC class I and class II gene polymorphisms with vaccine or challenge response to Salmonella enteritidis in young chicks , 2002, Immunogenetics.

[38]  Amita,et al.  Occurrence of Antibiotic Resistance Gene Cassettes aac(6′)-Ib, dfrA5, dfrA12, and ereA2 in Class I Integrons in Non-O1, Non-O139 Vibrio cholerae Strains in India , 2002, Antimicrobial Agents and Chemotherapy.

[39]  M. Molyneux,et al.  Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence , 2002, AIDS.

[40]  K. Killeen,et al.  Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine , 2002, Infection and Immunity.

[41]  R. Curtiss,et al.  Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium Vaccine , 2002, Infection and Immunity.

[42]  J. Galán,et al.  Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. , 2001, Vaccine.

[43]  M. Aepfelbacher,et al.  SopE and SopE2 from Salmonella typhimurium Activate Different Sets of RhoGTPases of the Host Cell* , 2001, The Journal of Biological Chemistry.

[44]  E. L. Hohmann.  Nontyphoidal salmonellosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Galán,et al.  Salmonella interactions with host cells: type III secretion at work. , 2001, Annual review of cell and developmental biology.

[46]  M. Levine,et al.  Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. , 2000, Vaccine.

[47]  Thorns Cj,et al.  Bacterial food-borne zoonoses. , 2000 .

[48]  E. Hohmann,et al.  Pilot Study of phoP/phoQ-DeletedSalmonella enterica Serovar Typhimurium ExpressingHelicobacter pylori Urease in Adult Volunteers , 2000, Infection and Immunity.

[49]  S. Kaufmann,et al.  Immune response to infection with Salmonella typhimurium in mice , 2000, Journal of leukocyte biology.

[50]  K. Darwin,et al.  Molecular Basis of the Interaction ofSalmonella with the Intestinal Mucosa , 1999, Clinical Microbiology Reviews.

[51]  J. Shea,et al.  Influence of the Salmonella typhimuriumPathogenicity Island 2 Type III Secretion System on Bacterial Growth in the Mouse , 1999, Infection and Immunity.

[52]  S. Maloy,et al.  Survival in a cruel world: how Vibrio cholerae and Salmonella respond to an unwilling host. , 1997, Genes & development.

[53]  M. Kagnoff,et al.  Genetically resistant (Ityr) and susceptible (Itys) congenic mouse strains show similar cytokine responses following infection with Salmonella dublin. , 1996, Journal of immunology.

[54]  D. Spriggs,et al.  Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. , 1995, The Journal of infectious diseases.

[55]  J. Hackett.  Use of Salmonella for heterologous gene expression and vaccine delivery systems. , 1993, Current opinion in biotechnology.

[56]  M. Levine,et al.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial , 1992, Infection and immunity.

[57]  J. Mekalanos,et al.  Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium , 1992, Infection and immunity.

[58]  B. Forrest,et al.  In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans. , 1991, Vaccine.

[59]  J. Galán,et al.  Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. , 1990, Gene.

[60]  C. Tacket,et al.  SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR , 1988, The Lancet.

[61]  D. Sack,et al.  B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. , 1987, The Journal of infectious diseases.

[62]  R. Peto.  THE HORSE-RACING EFFECT , 1981, The Lancet.